Pancreatin 8000 enteric-coated tablets 0.24g 50 pieces

Active ingredient: 1 tablet contains 0.24 g of pancreatin, which corresponds to an activity of at least 8000 lipolytic ph. eur. u., 5800 amylolytic ph. eur. u. and 380 proteolytic ph. eur. u.;

Excipients: microcrystalline cellulose, crospovidone, sodium chloride, colloidal silicon dioxide, magnesium stearate, methacrylate copolymer dispersion, talc, polyethylene glycol (macrogol), titanium dioxide (E 171), carmoisine (E 122).

The film-coated tablets are enteric-coated.

Main physicochemical properties: round tablets with a biconvex surface, coated with a pink coating. Two layers are visible at the border.

Digestive aids, including enzymes.

PBX code A09A A02.

Pharmacodynamics.

Enzyme preparation. Pancreatic enzymes (lipase, amylase and protease), which are part of it, facilitate the digestion of fats, carbohydrates, proteins, which contributes to their complete absorption in the small intestine. In diseases of the pancreas, the drug compensates for the insufficiency of its exocrine function and helps improve the digestive process.

Pharmacokinetics.

The acid-resistant shell of the tablets protects the enzymes from inactivation by gastric juice. Only under the influence of a neutral or slightly alkaline environment of the small intestine does the shell dissolve and the enzymes are released. The maximum enzymatic activity of the drug is observed 30-45 minutes after oral administration.

Diseases accompanied by disturbances in the process of food digestion due to insufficient secretion of digestive enzymes by the pancreas, such as chronic pancreatitis.

Conditions after simultaneous resection of the stomach and small intestine, functional acceleration of the passage of food through the intestines, intestinal disorders, simultaneous consumption of difficult-to-digest vegetable, fatty and unusual foods.

Intestinal bloating. Preparation for X-ray or ultrasound diagnostic examinations.

Hypersensitivity to the components of the drug, acute pancreatitis or chronic pancreatitis in the acute stage (but episodic exacerbation is possible in the phase of fading exacerbation when expanding the diet in the presence of pancreatic dysfunction).

Reduces iron absorption (especially with long-term use).

If the patient develops unusual abdominal symptoms or changes in the nature of the symptoms of the underlying disease, it is recommended to exclude the possibility of colon damage, especially if the patient uses a dose of more than 10,000 lipolytic ph. eur. u./kg/day.

The drug contains active enzymes that can damage the oral mucosa, up to the formation of ulcers, so the tablets should be swallowed whole, without chewing.

During pregnancy and breastfeeding, the drug is taken as prescribed by a doctor if the expected benefit to the mother outweighs the potential risk to the fetus or child.

There are no reservations.

The dose of the drug depends on the deficiency of pancreatic enzymes in the duodenum and is set individually.

If there are no other recommendations, as well as in cases of consumption of difficult-to-digest plant foods, fatty or unusual foods, take 1-2 tablets. In other cases, when digestive disorders occur, the recommended dose is 2-4 tablets. If necessary, the dose can be increased. Increasing the dose to reduce the symptoms of the disease, such as steatorrhea or abdominal pain, should be carried out only under the supervision of a doctor. The daily dose of lipase should not exceed 15,000-20,000 lipolytic Ph. Eur. U. per 1 kg of body weight.

The tablets are taken during meals, swallowed whole, with plenty of liquid, for example, a glass of water.

The duration of treatment depends on the course of the disease and is determined by the doctor individually.

The dosage of the drug and the duration of treatment for children are decided by the doctor. The drug is prescribed in a dose necessary for the normalization of stool, but not more than 1500 lipolytic Ph. Eur. U. per 1 kg of body weight of a child under 12 years of age. For children from 12 to 18 years of age, the daily dose of enzymes should not exceed 15000-20000 lipolytic Ph. Eur. U. lipase per 1 kg of body weight.

Used for children aged 6 years and over.

Hyperuricemia and hyperuricosuria have been observed when taking very high doses of other pancreatin preparations.

Treatment: therapy is symptomatic.

On the part of the immune system: allergic reactions, including rash, itching, sneezing, urticaria, lacrimation, bronchospasm, anaphylactic reactions. Allergic reactions are possible due to the content of carmoisine.

Gastrointestinal tract: diarrhea, abdominal pain, nausea, vomiting, change in stool pattern; possible development of intestinal obstruction, constipation, bloating.

If any adverse reactions occur, you should consult a doctor.

2 years.

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children!